Italy In-Vitro Diagnostics (IVD) Market Report by Test Types, Product, Application, Technology, End User, Cities and Companies Analysis 2026-2034

Italy IVD Market Size and Forecast 2026-2034

The Italy In-Vitro Diagnostic market is anticipated to exhibit sustainable growth owing to the rising demand for early diagnosis of diseases, growing incidence of chronic and infectious diseases, and the increasing use of sophisticated diagnostic methods. The market is projected to expand from US$ 2.91 billion in 2025 to US$ 4.34 billion in 2034 at a CAGR of 4.53% percent during 2026-2034. Growth in the aging population, advancements in the laboratory setup, and increasing investments in molecular diagnostics and automation of testing devices are some of the factors driving market growth in Italy.

Italy In-Vitro Diagnostics (IVD) Market Overview

IVD stands for In-Vitro Diagnostic Tests, which means diagnostic tests that are conducted on biological specimens like blood, urine, tissue, and saliva outside the body to diagnose, treat, and prevent diseases. In-vitro diagnostic technologies are essential in today's healthcare industry since they assist doctors in diagnosing infections, chronic conditions, gene-related issues, and cancer during their early stages. The commonly used in-vitro technologies include rapid diagnostic tests, molecular diagnostics, immunoassay technology, hematology systems, and clinical chemistry analyzers.

The rising demand for IVD devices in Italy has been driven by the country's excellent public healthcare system and the increasing elderly population that needs constant testing for various diseases related to their age. The Italian healthcare sector places a lot of importance on preventive medicine and early diagnosis, thus highlighting the significance of IVD technologies as a key tool in achieving this objective. The adoption of innovative technologies like automation, molecular testing, and POC diagnostic solutions has contributed towards the growth of this industry. Moreover, the coronavirus outbreak heightened the consciousness about testing for infectious diseases, thus boosting the usage of diagnostic solutions.

Top 10 Cities with Highest Aging Population in Italy

Rank City Estimated Population Aged 65+ (%) Key Demographic Insight

1 Trieste 28.40% One of Italy's oldest urban populations with very high elderly dependency ratio

2 Genoa 27.80% Liguria region has the highest aging index in Italy

3 Florence 26.50% High concentration of elderly residents and chronic disease burden

4 Bologna 25.90% Rapidly growing senior demographic and healthcare demand

5 Venice 25.70% Aging population driving long-term healthcare needs

6 Turin 25.30% Large elderly population with increasing chronic illnesses

7 Milan 24.90% Major metropolitan city with substantial aging residents

8 Rome 24.60% High number of older adults requiring healthcare support

9 Verona 24.20% Strong focus on geriatric healthcare services

10 Palermo 23.80% Growing elderly demographic in southern Italy

Sources: ISTAT Italy Demographic Data, Statista Aging Population in Italy, Population Ageing in Italian Municipalities Study

Top 10 Italian Cities Associated with High Burden of Age-Related Diseases

Rank City Key Age-Related Disease Burden Factors

1 Milan High elderly population, cardiovascular diseases, diabetes, and cancer prevalence

2 Rome Large aging population with rising chronic disease and neurological disorder cases

3 Naples Increased cardiovascular and metabolic disease burden among elderly residents

4 Turin High prevalence of age-related chronic illnesses and respiratory diseases

5 Genoa One of Italy's oldest urban populations with significant geriatric healthcare demand

6 Bologna Growing elderly demographic and strong demand for chronic disease monitoring

7 Florence Rising incidence of dementia, cardiovascular disease, and diabetes

8 Venice Aging population linked to higher long-term healthcare and diagnostic needs

9 Palermo Increasing burden of chronic diseases among older adults

10 Verona Strong focus on geriatric healthcare and age-related disease management

Sources: OECD Italy Health Profile 2025, Statista Aging Population in Italy, Population Ageing in Italian Municipalities Study

Drivers of Growth in the Italy In-Vitro Diagnostics (IVD) Market

Increasing Incidence of Chronic and Age-Related Diseases

The Italian population is among the most elderly populations in Europe, and hence, there is an increasing incidence of chronic and age-related ailments such as diabetes, heart diseases, cancers, and neurological problems. There is also a rising demand for frequent testing procedures that aid in the early diagnosis and effective monitoring of the patients during the course of their treatment. In Vitro Diagnostics tools are essential when it comes to assessing the state of health of the patients, making decisions in clinics, and enhancing the results of treating various diseases. The need for preventive medicine and regular screening is driving public and private organizations to invest heavily in diagnostic services and laboratory equipment. In addition, the elderly population in Italy continues to put extra strain on the healthcare facilities in the region. It is estimated that Italy is one of the oldest nations in the European Union, where close to 25% of its inhabitants are over 65 years old.

Government Investment and National Screening Programs

In Italy, further advancements in the healthcare segment can be achieved through investments in various national screening programs and preventive healthcare measures for cancer, infectious disease, and genetic conditions. The use of highly advanced in vitro diagnostics (IVD) in these programs ensures prompt and accurate diagnosis among individuals and helps in reducing the burden of many diseases. With more funding and alignment of healthcare initiatives with those of other European Union member states, the laboratory facilities in Italy will undergo modernization to improve the use of advanced diagnostic tools. Moreover, public education and awareness programs and government-funded screening have been key contributors to increased volumes of diagnostic tests performed in Italy, thus emphasizing the significance of the IVD technology in Italy. Healthcare innovations and the provision of advanced treatment and diagnosis remain top priorities in Italy. For example, in December 2024, the Italian Senate approved the 2025 budget package, including tax breaks for innovative antibiotics and the Fund for Innovative Medicines.

Technological Advancements and Laboratory Automation

The Italian In-Vitro Diagnostics sector is witnessing significant changes due to the emergence of laboratory automation, digital diagnostics, and molecular diagnostic tests. There is an ongoing trend towards the acquisition of cutting-edge diagnostic tools that enable fast and efficient diagnosis, along with the ability to conduct high-throughput tests. Chemiluminescence Immunoassay tests (CLIA), Polymerase Chain Reaction test (PCR), and next-generation sequencing have gained much importance in oncology, infectious diseases, and personalized medicine diagnostics. The healthcare laboratories in Italy are modernizing their facilities to achieve precise diagnostics with increased efficiency and reduced human interventions. This process will help to strengthen the diagnostic capacity of the nation while aligning with its healthcare modernization objectives. In August 2022, DIESSE Diagnostica Senese collaborated with Grifols to provide Promonitor biological drug monitoring kits via point-of-care and ELISA microplate technology-based systems.

Challenges in the Italy In-Vitro Diagnostics (IVD) Market

Regional Disparities in Healthcare Access

As a result of decentralization in healthcare in Italy, there are great discrepancies in the provision of diagnostic services within different areas of the country. Northern regions usually have more developed healthcare infrastructure, well-developed laboratories, and increased accessibility to advanced In-Vitro Diagnostics. Several regions of the South of Italy continue to experience the absence of healthcare infrastructure and resources, funding, and diagnostic facilities. This factor influences the equality of healthcare services and the ability of people living in certain regions of Italy to be diagnosed at an early stage and receive effective treatment. There is also a difference in the modernity of laboratory equipment, number of medical personnel, and technological advancements in diagnostic services in Italy, which affects its effectiveness and efficiency. Overall, the discrepancy in healthcare resources negatively impacts the development of the IVD sector in the country. It is important to address this issue to improve healthcare policies and invest in the infrastructure and diagnostic technology to provide patients in all Italian regions with high-quality healthcare services.

Cost Limitations and Reimbursement Challenges

Despite Italy maintaining a publicly financed healthcare system, financial considerations and reimbursement obstacles still affect the adoption of novel diagnostics solutions. The high expenses of molecular diagnostics, automation, and specialized testing can lead to increased expenditure burdens for both health care systems and laboratories. Moreover, the approval process for reimbursement in some cases is slow and unpredictable, especially in relation to newly launched or extremely specialized IVD devices. In most situations, new diagnostics are partly reimbursed. Financial considerations become a barrier for some clinics and laboratories to upgrade existing machinery or acquire new diagnostics technology. Additionally, finding the balance between affordable healthcare services and technological advancements is one of the crucial issues in health care policy. The financial situation inside the public healthcare system may become an obstacle for implementing innovative diagnostics solutions in certain regions. Thus, reimbursement restrictions and financial barriers continue to affect innovation and growth in the Italian IVD market.

Italy ELISA & CLIA In-Vitro Diagnostics (IVD) Market

ELISA (Enzyme-Linked Immunosorbent Assay) and CLIA (Chemiluminescence Immunoassay) technology form key segments in the Italian In-Vitro Diagnostics industry. Both types of assays are popularly used for diagnosing infections, hormone abnormalities, autoimmune diseases, and cancers owing to their sensitivity, precision, and automation. The need for early diagnosis and preventative care in Italy is increasing the demand for immunoassays that can diagnose a range of conditions including HIV, hepatitis, and cancer. Italian hospitals and laboratories are turning to cutting-edge CLIA systems to benefit from faster processing speeds, increased testing capacity, and enhanced lab efficiency. Automation in ELISA and CLIA systems is reducing the possibility of human error and enabling mass diagnostic testing campaigns. The rise in chronic diseases, along with rising investment in health care services, will help boost market growth. With Italy's efforts towards upgrading its laboratory infrastructure and implementing disease surveillance initiatives, the demand for immunoassay solutions is likely to increase consistently throughout the forecast period.

Italy In-Vitro Diagnostics (IVD) Rapid Test Market

The IVD rapid test sector in Italy shows promising growth because of the growing preference for efficient, speedy, and easily available methods of diagnosis. The rapid test can be utilized in clinics and homes, which is why there has been an increased demand for such diagnostic tools during the last decade. Rapid tests have become an essential part of diagnostics for infectious and chronic diseases, pregnancy tests, and preventive healthcare screenings. The COVID-19 pandemic became an important factor that contributed to the heightened popularity of rapid testing across the country. Increased numbers of elderly citizens and rising interest in home healthcare services become another impetus behind the expansion of the market. The availability of fast testing kits allows patients to have convenient ways to determine their condition, and the absence of laboratory equipment at homes does not affect the accessibility of this method anymore. Governmental encouragement of decentralized healthcare systems and preventive care initiatives plays an important role in accelerating the development of the industry as well.

Italy In-Vitro Diagnostics (IVD) Instruments Market

There is an increase in the number of diagnostic instruments used in Italy due to increased laboratory automation, healthcare digitization, and high demand for high throughput and highly efficient diagnostic systems. Hospitals, research centers, and clinical laboratories have been allocating considerable funds to purchase advanced diagnostic devices, including hematology analyzers, molecular diagnostics, immunoassay analyzers, and clinical chemistry. The healthcare organizations in Italy are focused on investing in devices that enhance the testing process's accuracy and precision, minimize errors, and cut down the time required to diagnose patients. It is essential to ensure that these diagnostic devices integrate well with the Laboratory Information Management Systems (LIMS) to increase their effectiveness. With the increase in the number of individuals with chronic diseases and infections, there is an increase in testing volumes in healthcare institutions, necessitating the procurement of scalable and automatic testing devices.

Italy In-Vitro Diagnostics (IVD) Infectious Disease Market

The Italian IVD infectious disease market will continue to be significant due to the need for proper diagnosis for infectious diseases like COVID-19, influenza, HIV, hepatitis, and sexually transmitted diseases. Italian public health agencies remain dedicated to early disease detection and surveillance efforts in order to prevent disease outbreaks, which involve national screenings and diagnostic testing. Molecular diagnostics, antigen-based assays, and rapid diagnostic technologies are extensively used in central laboratories, hospitals, and healthcare facilities for point-of-care testing. Investments in the development of diagnostic tools and laboratory capacity have been increased in recent times in anticipation of pandemics and the need to manage infectious diseases. The usage of syndromic testing panels and multiplex molecular diagnostics has also gained popularity since they allow multiple pathogen detection at once, making treatment decisions easier. Surveillance programs and investments in healthcare improvements supported by the government are also likely to contribute significantly to the growth of the market. The Italian IVD infectious disease market is projected to experience steady growth for many years due to the significance of infectious disease monitoring in its healthcare system.

Italy In-Vitro Diagnostics (IVD) Clinical Chemistry Market

Clinical Chemistry is one of the key segments of the diagnostic tests market in Italy and is used extensively for disease diagnosis and prevention of illnesses by the healthcare service providers. The types of clinical chemistry test include glucose test, electrolyte test, liver function test, kidney function test, and metabolic panel test. These tests are very important to identify and monitor various chronic diseases such as diabetes, heart ailments, and kidney problems that have been on the increase with the aging Italian population. There has been emphasis in Italian health institutions and laboratories in automation and laboratory processes to help them be more efficient. As such, there has been widespread adoption of automated clinical chemistry analyzers with the ability to perform large-scale tests with low maintenance costs. The introduction of advanced clinical chemistry analyzers offers better precision and fast results in healthcare institutions. In light of the rising awareness about healthcare services and preventive medicine in Italy, there has been increased demand for clinical chemistry tests in Italy.

Italy In-Vitro Diagnostics (IVD) Laboratories Market

Laboratories act as a pivotal component of Italy's In-Vitro Diagnostic market through carrying out extensive diagnostic testing activities in hospitals, independent laboratories, and specialized medical centers. The Italian In-Vitro Diagnostic market features an amalgamation of both public and privately run lab networks, which have been making increasing use of automation, digital health solutions, and assisted diagnostics through AI. A significant portion of diagnostic activity takes place in centralized laboratories or in-lab testing facilities, especially those located in well-equipped healthcare settings within urban areas. Extensive use of LIS and other digital solutions is becoming common to improve efficiencies in terms of operational workflows and patient data management. Nonetheless, due to healthcare decentralization in some regions, there may be disparities in the availability of diagnostic testing services, as well as laboratory capacity in the north and south of Italy. Increasing demands for healthcare services necessitate improved test volume, quality control, and advanced diagnostic capabilities in laboratories throughout the country.

Rome IVD Market

The IVD market in Rome has seen steady growth owing to the advanced healthcare structure in the city, the need for early disease identification, and the involvement of numerous healthcare organizations. Several hospitals and diagnostic centers in Rome have started utilizing new IVD technology to diagnose infectious disease, cancer, diabetes, heart diseases, and genetic ailments accurately and rapidly. The increased number of elderly patients and chronic diseases are some of the significant drivers of the market in terms of demand. Besides, government initiatives for the development of healthcare and the use of technologies such as digitization have contributed to the adoption of automation technology and molecular diagnostics in hospitals and laboratories. There are numerous medical activities and innovations taking place at research and academic institutions in Rome, which can also be considered a key factor for the growth of the market. The increased application of point-of-care diagnostic tools and personalized medicine by healthcare organizations have been witnessed recently.

Milan IVD Market

The Milan IVD market is among the most sophisticated in terms of diagnostic technology in Italy, thanks to the presence of a highly developed healthcare ecosystem, thriving biotech industry, and a cluster of leading medical institutions in the region. Milan acts as an epicenter for healthcare innovation, research collaboration, and advanced laboratory testing services, thus fueling the demand for next-generation in-vitro diagnostic solutions. Increasing reliance on molecular diagnostics, immunoassays, hematology analyzers, and automation platforms at diagnostic laboratories and hospitals in Milan will continue to drive the market growth. The incidence rates of chronic illnesses, infections, and cancer will fuel the demand for more advanced diagnostic testing solutions. Moreover, the emerging trend toward personalized healthcare and preventive care is driving the adoption of genetic testing and biomarkers. Other factors contributing to market growth include well-established healthcare infrastructure and extensive funding for medical research in Milan. Digital pathology and artificial intelligence-powered diagnostic devices are being deployed by healthcare institutions to enhance operational performance, making the Milan IVD market highly promising in the long run.

Naples IVD Market

The Naples IVD market is experiencing steady growth owing to growing healthcare investments, high levels of awareness with regard to preventive healthcare practices, and an increase in diagnostic tests offered in the area. Increasing use of innovative diagnostic tools within healthcare facilities in Naples to enable early diagnosis and effective treatment of chronic and infectious diseases is one of the factors propelling the market forward. There is growing need for blood testing, microbiology testing, molecular testing, and clinical chemistry testing in Naples, which fuels the development of the market. Increasing prevalence of diabetes, cardiovascular diseases, and respiratory diseases, combined with aging populations, results in the growing demand for laboratory services. Furthermore, government healthcare programs that focus on expanding access to diagnostics and improving healthcare infrastructure contribute to the development of the market. Portable point-of-care diagnostic tools gain popularity because of fast diagnostic results they enable, thus improving the quality of patient care delivery.

Turin IVD Market

There has been an ongoing growth in the IVD market of Turin due to its industrial strength, its strong research potential, and advancements in technology. Health care providers are becoming more concerned about investing in innovative in vitro diagnostic solutions that help in improving their services. Increasing health care awareness, prevalence of diseases, and need for personalized treatments have been driving the Turin market towards innovations in health care technologies and processes. There has been growing interest in molecular diagnostics, immunodiagnostics, and genetic tests as healthcare providers become more focused on offering precision medicine and timely disease diagnosis. The strong research infrastructure of Turin and collaboration between health care providers and biotechnology companies are helping to further drive innovations in diagnostics. With advancements in digital health care technology and implementation of AI in laboratory diagnostics, testing is being performed more efficiently than before. Increased demand for automation of laboratory processes, and point-of-care tests is also being seen by the healthcare facilities in Turin.

Key Segments in the Italy IVD Market

Test Types

• ELISA & CLIA
• PCR
• Rapid Test
• Fluorescence Immunoassays (FIA)
• In Situ Hybridization
• Transcription Mediated Amplification
• Sequencing
• Colorimetric Immunoassay
• Radioimmunoassay (RIA)
• Isothermal Nucleic Acid Amplification Technology
• Others

Product

• Services
• Instruments
• Reagents

Application

• Infectious Disease
• Diabetes
• Cardiology
• Oncology
• Nephrology
• Autoimmune Diseases
• Drug Testing
• Other Applications

Technology

• Immunoassay
• Clinical Chemistry
• Molecular Diagnostics/Genetics
• Hematology
• Microbiology
• Coagulation
• Others

End User

• Hospitals
• Laboratories
• Home Care
• Others

Cities

• Rome
• Milan
• Naples
• Turin
• Palermo
• Genoa
• Bologna
• Florence
• Bari
• Catania
• Rest of Cities

All companies have been covered with 5 Viewpoints

• Overviews
• Key Person
• Recent Developments
• SWOT Analysis
• Revenue Analysis

Key Players

• Roche Diagnostics
• Abbott Diagnostics
• Siemens Healthineers
• Danaher Corporation
• Thermo Fisher Scientific
• Sysmex Corporation